Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Proceeds from disposition of marketable securities and other investments

Proceeds from disposition of marketable securities and other investments at other companies

Hyatt Hotels logo
Hyatt HotelsH
$186M+38.8%
Cboe Global Markets logo
Cboe Global MarketsCBOE
$1.5M-67.4%
Atlassian logo
AtlassianTEAM
$352.09M+17,522%
Evercore logo
EvercoreEVR
$0-100%
Royalty Pharma logo
Royalty PharmaRPRX
$375K—
Popular logo
PopularBPOP
——

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's proceeds from disposition of marketable securities and other investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's proceeds from disposition of marketable securities and other investments?
BioMarin Pharmaceuticals (BMRN) reported proceeds from disposition of marketable securities and other investments of $767.28M in Q1 2026.
How has BioMarin Pharmaceuticals's proceeds from disposition of marketable securities and other investments changed year-over-year?
BioMarin Pharmaceuticals's proceeds from disposition of marketable securities and other investments increased by 886.2% year-over-year, from $77.8M to $767.28M.
What is the long-term trend for BioMarin Pharmaceuticals's proceeds from disposition of marketable securities and other investments?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's proceeds from disposition of marketable securities and other investments has grown at a -16.4% compound annual growth rate (CAGR), from $691.05M to $337.8M.